We evaluated the effect of DMTs on Covid-19 severity in patients with MS, with a pooled-analysis of two large cohorts from Italy and France. The association of baseline characteristics and DMTs with Covid-19 severity was assessed by multivariate ordinal-logistic models and pooled by a fixed-effect meta-analysis. 1066 patients with MS from Italy and 721 from France were included. In the multivariate model, anti-CD20 therapies were significantly associated (OR = 2.05, 95%CI = 1.39–3.02, p < 0.001) with Covid-19 severity, whereas interferon indicated a decreased risk (OR = 0.42, 95%CI = 0.18–0.99, p = 0.047). This pooled-analysis confirms an increased risk of severe Covid-19 in patients on anti-CD20 therapies and supports the protective role of interferon.
DMTs and Covid-19 severity in MS. a pooled analysis from Italy and France / Sormani, M. P.; Salvetti, M.; Labauge, P.; Schiavetti, I.; Zephir, H.; Carmisciano, L.; Bensa, C.; De Rossi, N.; Pelletier, J.; Cordioli, C.; Vukusic, S.; Moiola, L.; Kerschen, P.; Radaelli, M.; Theaudin, M.; Immovilli, P.; Casez, O.; Capobianco, M.; Ciron, J.; Trojano, M.; Stankoff, B.; Creange, A.; Tedeschi, G.; Clavelou, P.; Comi, G.; Thouvenot, E.; Battaglia, M. A.; Moreau, T.; Patti, F.; De Seze, J.; Louapre, C.. - In: ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY. - ISSN 2328-9503. - 8:8(2021), pp. 1738-1744. [10.1002/acn3.51408]
DMTs and Covid-19 severity in MS. a pooled analysis from Italy and France
Salvetti M.;
2021
Abstract
We evaluated the effect of DMTs on Covid-19 severity in patients with MS, with a pooled-analysis of two large cohorts from Italy and France. The association of baseline characteristics and DMTs with Covid-19 severity was assessed by multivariate ordinal-logistic models and pooled by a fixed-effect meta-analysis. 1066 patients with MS from Italy and 721 from France were included. In the multivariate model, anti-CD20 therapies were significantly associated (OR = 2.05, 95%CI = 1.39–3.02, p < 0.001) with Covid-19 severity, whereas interferon indicated a decreased risk (OR = 0.42, 95%CI = 0.18–0.99, p = 0.047). This pooled-analysis confirms an increased risk of severe Covid-19 in patients on anti-CD20 therapies and supports the protective role of interferon.| File | Dimensione | Formato | |
|---|---|---|---|
|
Sormani_DMTsCovid-19-severity_2021.pdf
accesso aperto
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Creative commons
Dimensione
321.4 kB
Formato
Adobe PDF
|
321.4 kB | Adobe PDF | |
|
Sormani_Affiliation_DMTsCovid-19-severity_2021.pdf
accesso aperto
Tipologia:
Altro materiale allegato
Licenza:
Creative commons
Dimensione
112.55 kB
Formato
Adobe PDF
|
112.55 kB | Adobe PDF |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
